Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

GILT Docetaxel - Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00174629
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 7, 2009
Information provided by:

Brief Summary:

Primary Objective:

  • To compare response rate between genotypic groups and control group.

Secondary Objective:

  • To determine the safety, time to treatment failure and survival in control and genotypic arms.

Condition or disease Intervention/treatment Phase
Lung Neoplasms Drug: Docetaxel/DDP Drug: docetaxel/gemcitabine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 449 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients
Study Start Date : June 2001
Actual Primary Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: 1 Drug: docetaxel/gemcitabine
Active Comparator: 2 Drug: Docetaxel/DDP

Primary Outcome Measures :
  1. Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.

Secondary Outcome Measures :
  1. Time to treatment failure and survival [ Time Frame: calculated from the registration date until progression or death, respectively ]
  2. Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria. [ Time Frame: before each cycle ]
  3. Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening. [ Time Frame: Throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must be/have:

  • histologically confirmed non-small cell lung cancer (squamous cell carcinoma, large cells or adenocarcinoma; it is recommended to provide the full paraffin-embedded block or at least 5 5 sections obtained from the primary tumor, recurrence or metastasis, not stained, fixed in formalin/embedded in paraffin, mounted on slides (10 micron sections), as well as two serum samples in two 10-ml tubes and two blood samples (see appendix X);
  • unresectable metastatic (stage IV or IIIB malignant pleural effusion) NSCLC;
  • WHO performance status < 2;
  • Adequate bone marrow, hepatic and renal functions, assessed during the previous 14 days, that should be shown by the following characteristics:

    • hemoglobin > or = 10g/dl and no blood cell transfusion within the previous 2 weeks;
    • absolute neutrophil count > 2.0 10^9 cells/l;
    • platelet count > or = 100.10^9 cells/l;
    • no evidence of myelodysplastic syndrome or abnormal bone marrow reserve;
    • creatinine < or = 1.5 x UNL or creatinine clearance > or = 60 ml/min (real or calculated);
    • total bilirubin < or = UNL;
    • ASAT (SGOT) and/or ALAT (SGPT) < or = 1.5 x UNL;
    • alkaline phosphatases < or = 5 x UNL;
    • serum calcium < or = 1.1 x UNL;
  • at least one measurable lesion;
  • previous surgery intervention (more than 30 days before inclusion in the study) is allowed but metastatic disease must be demonstrated;
  • previous radiotherapy is allowed if:

    • less or equal to 10% of bone marrow has been irradiated
    • end of radiotherapy 21 days or more prior to inclusion in the study;
    • patient has fully recovered from all toxic effects;
    • at least one of the measurable target lesions for evaluation of tumor response has not been irradiated;
  • the patient must be accessible for treatment and follow-up. The patient entered into this trial must be treated and followed up at the participating center;
  • life expectancy > or = 12 weeks;
  • The initial diagnostic procedures should be performed during the 4 weeks prior to the randomization.

Exclusion Criteria:

  • pregnant or lactating women (women of childbearing potential must use adequate contraception);
  • prior systemic chemotherapy or immunotherapy for NSCLC, even as neoadjuvant or adjuvant therapy;
  • prior malignancies, except cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with non-evidence of disease for at least 5 years;
  • history or clinical symptomatic brain or leptomeningeal metastases;
  • current peripheral neuropathy and neurohearing > or = NCIC-CTG grade 2 except if due to trauma;
  • other serious illness or medical condition, including:

    • congestive heart disease; prior myocardial infarction within 6 months;
    • history of significant neurologic or psychiatric disorders that would inhibit their understanding and giving of informed consent;
    • infection requiring I.V. antibiotics and tuberculosis under treatment ongoing at study entry;
    • untreated superior vena cava syndrome;
    • active peptic ulcer; unstable diabetes mellitus or other contraindication to high dose corticotherapy such as herpes, herpes zoster, cirrhosis;
  • hypercalcemia requiring therapy;
  • preexisting ascitis and/or clinical significant pericardial effusion;
  • patients whose lesion(s) are assessable only by radionuclide scan;
  • history of allergy to drugs containing the excipient TWEEN 80®;
  • concurrent treatment with other investigational drugs;
  • participation in a clinical trial of one or more investigational agents (i.e. antibiotic) or devices within 30 days of study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00174629

Layout table for location information
Berlin, Germany
Barcelona, Spain
Genève, Switzerland
Sponsors and Collaborators
Layout table for investigator information
Study Director: Jean-Philippe Aussel Sanofi
Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00174629    
Other Study ID Numbers: TAX_ES1_302
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: December 7, 2009
Last Verified: December 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators